KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2021 - 2025)

Historic Long-Term Debt Repayments for Alnylam Pharmaceuticals (ALNY) over the last 3 years, with Q4 2025 value amounting to $52.3 million.

  • Alnylam Pharmaceuticals' Long-Term Debt Repayments changed N/A to $52.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.5 billion, marking a year-over-year decrease of 4371.61%. This contributed to the annual value of $1.2 billion for FY2025, which is N/A changed from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Long-Term Debt Repayments stood at $52.3 million for Q4 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Long-Term Debt Repayments ranged from a high of $500.0 million in Q4 2021 and a low of -$1.5 billion during Q4 2022
  • Moreover, its 3-year median value for Long-Term Debt Repayments was $52.3 million (2025), whereas its average is -$324.0 million.
  • The largest annual percentage gain for Alnylam Pharmaceuticals' Long-Term Debt Repayments in the last 5 years was 40484.28% (2022), contrasted with its biggest fall of 40484.28% (2022).
  • Quarter analysis of 3 years shows Alnylam Pharmaceuticals' Long-Term Debt Repayments stood at $500.0 million in 2021, then crashed by 404.84% to -$1.5 billion in 2022, then surged by 103.43% to $52.3 million in 2025.
  • Its Long-Term Debt Repayments was $52.3 million in Q4 2025, compared to -$1.5 billion in Q4 2022 and $500.0 million in Q4 2021.